(Q40570930)

21 September 2017

title

Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr. (English)

1 reference

21 September 2017

main subject

acute myeloid leukemia

1 reference

Felicetto Ferrara

1

1 reference

21 September 2017

Adriano Venditti

2

1 reference

21 September 2017

Angelo Michele Carellajr

3

1 reference

21 September 2017

Nicola Cantore

4

1 reference

21 September 2017

Francesco Buccisano

5

1 reference

21 September 2017

Anna Tamburini

6

1 reference

21 September 2017

Salvatore Palmieri

7

1 reference

21 September 2017

Giuseppina Mele

8

1 reference

21 September 2017

Mario Annunziata

9

1 reference

21 September 2017

Michele Mario Greco

10

1 reference

21 September 2017

Sergio Amadori

11

1 reference

21 September 2017

publication date

1 October 2002

1 reference

European Journal of Haematology

21 September 2017

published in

1 reference

21 September 2017

volume

69

1 reference

21 September 2017

issue

4

1 reference

21 September 2017

page(s)

200-204

1 reference

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

The challenge of acute myeloid leukemia in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

Acute myeloid leukemia in the elderly: biology and therapeutic strategies.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: an interim report

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

High-dose idarubicin and busulphan as conditioning for autologous stem cell transplantation in acute myeloid leukemia: a feasibility study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2002.02806.X

7 January 2021

10.1034/J.1600-0609.2002.02806.X

Identifiers

DOI

1 reference

21 September 2017

1 reference